Evidence map›Paper›PMID 38888615›Full record

ArticleAnnals of hematology2024

Myeloproliferative neoplasm with eosinophilia and coexisting BCR::ABL1 and PDGFRB rearrangement: favorable and rapid response to imatinib.

Sun Yao, Liu Na, Hu Liangding

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Annals of hematology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Sun YaoSenior Department of Hematology, the Fifth Medical Center of Chinese People's Liberation Army General Hospital, Beijing, China.
Liu NaSenior Department of Hematology, the Fifth Medical Center of Chinese People's Liberation Army General Hospital, Beijing, China.
Hu LiangdingSenior Department of Hematology, the Fifth Medical Center of Chinese People's Liberation Army General Hospital, Beijing, China. huliangding@sohu.com.

Funding

the National Natural Science Foundation of China 82100239
6 · The paper itself

Abstract

Here, we present a rare case of myeloproliferative neoplasms (MPN) with eosinophilia harboring both BCR::ABL1 and PDGFRB rearrangements, posing a classification dilemma. The patient exhibited clinical and laboratory features suggestive of chronic myeloid leukemia (CML) and myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions (MLN-TK), highlighting the diagnostic challenges associated with overlapping phenotypes. Despite the complexity, imatinib treatment swiftly achieved deep molecular remission, underscoring the therapeutic efficacy of tyrosine kinase inhibitors in such scenarios. Furthermore, the rapid attainment of deep remission by this patient in response to imatinib closely resembles that observed in MLN-TK patients with PDGFRB rearrangements. Further research is warranted to elucidate the underlying mechanisms driving the coexistence of multiple oncogenic rearrangements in MPNs and to optimize therapeutic strategies for these complex cases.

Indexed as

EosinophiliaFusion Proteins, bcr-ablImatinib MesylateMyeloproliferative DisordersReceptor, Platelet-Derived Growth Factor betaGene RearrangementHumansMaleProtein Kinase InhibitorsYoung AdultFusion Proteins, bcr-ablImatinib MesylatePDGFRB protein, humanProtein Kinase InhibitorsReceptor, Platelet-Derived Growth Factor betaBCR:ABL1CMLMLN-TKMPNPDGFRB

Identifiers

PMID38888615

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.